<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017485</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068696</org_study_id>
    <secondary_id>P30CA016056</secondary_id>
    <secondary_id>RPCI-DS-95-34</secondary_id>
    <secondary_id>NCI-G01-1953</secondary_id>
    <nct_id>NCT00017485</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer</brief_title>
  <official_title>A Phase I Study Of Photodynamic Therapy (PDT) For The Treatment Of Basal Cell Carcinoma (BCC): A Drug/Light Dose Finding Study Utilizing 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A (HPPH-PHOTOCLOR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to&#xD;
      light to kill tumor cells. Photosensitizing drugs such as HPPH are absorbed by cancer cells&#xD;
      and, when exposed to light, become active and kill the cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of photodynamic therapy with HPPH in&#xD;
      treating patients who have basal cell skin cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of HPPH used in photodynamic therapy in patients with basal cell&#xD;
           skin cancer.&#xD;
&#xD;
        -  Determine the drug dose, light dose, and treatment interval combinations that do not&#xD;
           produce excessive toxicity to normal skin but effect tumor response in these patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the length of time for cutaneous photosensitivity in these patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Determine the plasma clearance rates for HPPH in these patients.&#xD;
&#xD;
        -  Determine the best combination of treatment parameters for a phase II study.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive HPPH IV on day 1. Patients undergo phototherapy on days 2-3.&#xD;
&#xD;
      Cohorts of 2-6 patients receive escalating doses of HPPH and phototherapy to determine the&#xD;
      minimum erythemal dose (MED). The MED is defined as the dose combination of HPPH and laser&#xD;
      light preceding that at which at least 1 patient experiences grade 3 or worse toxicity or at&#xD;
      which at least 2 patients experience grade 1 or worse toxicity.&#xD;
&#xD;
      Patients are followed daily for 4 days, at week 1, and at months 1, 3, 6, 12, and 24.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 4-25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">6</enrollment>
  <condition>Non-melanomatous Skin Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPPH</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-morpheaform basal cell skin cancer&#xD;
&#xD;
               -  Primary disease OR&#xD;
&#xD;
               -  Recurrent disease after prior therapy (e.g., surgical excision,&#xD;
                  electrodesiccation, cryosurgery, or radiotherapy)&#xD;
&#xD;
          -  At least 4 lesions, no greater than 2 cm in diameter and no greater than 5 mm in depth&#xD;
&#xD;
          -  No lesions located on the eyelid, nose, ear, periauricular area, genitals, or digits,&#xD;
             or any other lesions thought to be deep and/or aggressive&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 120,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  PT/PTT no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin no greater than 3.0 mg/dL&#xD;
&#xD;
          -  Liver enzymes no greater than 2 times ULN&#xD;
&#xD;
          -  No impaired hepatic function&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No impaired renal function&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No porphyria&#xD;
&#xD;
          -  No known hypersensitivity to porphyrins&#xD;
&#xD;
          -  No systemic lupus erythematosus&#xD;
&#xD;
          -  No history of positive antinuclear antibody&#xD;
&#xD;
          -  No history of degenerative disease of the retina&#xD;
&#xD;
          -  No xeroderma pigmentosum&#xD;
&#xD;
          -  No pancreatic disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 months since prior combination doxorubicin and radiotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan R. Oseroff, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 3, 2011</last_update_submitted>
  <last_update_submitted_qc>March 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alan Oseroff, MD</name_title>
    <organization>Roswell Park Cancer Institute</organization>
  </responsible_party>
  <keyword>basal cell carcinoma of the skin</keyword>
  <keyword>recurrent skin cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

